SUPPORT SERVICES
THAT
CAN HELP YOUR
PATIENTS
STAY ON
TRACK WITH TYSABRI

Biogen is committed to helping people living with RMS. We can provide assistance once your patients are prescribed a Biogen treatment, such as TYSABRI® (natalizumab). Biogen Support Services provides a variety of financial and insurance assistance options and other resources to help your patients get started on TYSABRI® (natalizumab). We’re here to be a resource for your patients. And we’re just a phone call away at 1-800-456-2255. Hablamos español. 

financial and insurance assistance - icon

Financial & Insurance Assistance

When TYSABRI treatment cost may be a concern for your patients, Biogen is here to help them start and continue on TYSABRI.

We will work with your patients based on their individual needs. Biogen Support Services provides a variety of financial and insurance assistance options and other resources to help your patients get started on TYSABRI, including:

  • Communicating with insurance companies to clarify and confirm coverage, including assistance with the Prior Authorization process and denied claims
  • Insurance counseling that educates uninsured and underinsured patients on government insurance programs
    • If your patients need assistance with the Affordable Care Act, we can help patients and providers become familiar with insurance options
  • Financial assistance includes:
    • A summary of benefits for each patient with a completed benefits investigation
    • The Biogen Copay Program, which may lower medication cost for eligible patients with commercial insuranceª
    • An Infusion Copay Assistance Program, providing up to $250 for eligible patients

aEffective January 1, 2021, there is an annual cap on the amount of assistance that patients can receive over a 1-year period. Federal and state laws and other factors may prevent or otherwise restrict eligibility. People covered by Medicare, Medicaid, the VA/DoD, or any other federal plans are not eligible to enroll. You are eligible to enroll in the Biogen Copay Program for as long as it is offered and you are treated with a Biogen relapsing MS medication. The Biogen Copay Program is no longer available for TECFIDERA patients in the states of Massachusetts and California.

Start eligible patients without extended insurance delays
 
case managers icon

Biogen Case Managers

Biogen Case Managers (Support Coordinators) are here to help your patients start and continue on TYSABRI. A Biogen Case Manager will reach out to your patient after they are prescribed TYSABRI.

Biogen Case Managers will also:

  • Educate your patients on financial assistance options available for TYSABRI
  • Provide patient status updates to your office to help you stay up-to-date with their TYSABRI treatment
  • Connect patients to free anti-JCV antibody testing and infusion site information
  • Investigate patient benefits to help determine the best coverage options for your patients, including assistance with the process of prior authorizations and denied claims
tysabri ongoing support icon

Nurse Educators

Nurse Educators are registered nurses. Many are MS-certified and are here for your patients who are prescribed TYSABRI. Nurse Educators are here to:

  • Help your patients understand what to expect during TYSABRI infusions
  • Give information that may help manage common TYSABRI side effects
  • Provide education about available resources for TYSABRI patients

A Nurse Educator can come to your office and educate your staff about how they can help support your patients on TYSABRI. Nurse Educators also communicate with you about your patients’ treatment start date and any treatment challenges they have expressed.

tysabri ongoing support icon

TYSABRI Ongoing Support Program

The optional TYSABRI Ongoing Support Program provides patients with periodic check-ins from Biogen Case Managers (Support Coordinators) and Nurse Educators to assess patients’ progress on therapy and to answer any questions they may have about their treatment with TYSABRI.b

Once patients are registered in the TOUCH® Prescribing Program, they are automatically enrolled to participate in the TYSABRI Ongoing Support Program.

  • After the patient's first TYSABRI infusion, the Nurse Educator introduces themself, asks the patient about their experience, and addresses treatment questions
  • The Nurse Educator will connect with the patient every 3 months to provide product and disease education, discuss their infusion experience, verify Risk Evaluation and Mitigation Strategy (REMS) requirements, and identify and help address barriers to treatment, including travel, financial assistance, shipments, infusions, reauthorizations, and site of care (SOC) location
  • As their 1-year anniversary on TYSABRI approaches, a Nurse Educator will check in with the patient once again and continue to follow up about every 6 months thereafter

Patients can opt out of the TYSABRI Ongoing Support Program at any time and continue to take advantage of resources offered through Biogen Support Services. Your office may also opt out of the program on behalf of your patients.

bPatient consent is required before a Biogen Case Manager or Nurse Educator can contact your patient.

TOUCH Prescribing Program

TOUCH® Prescribing Program

The TOUCH® Prescribing Program is designed to inform prescribers, pharmacies, administration sites, and patients about the risk of progressive multifocal leukoencephalopathy (PML) associated with TYSABRI. The program also provides real-time access to patient data and can help maintain compliance.

Learn more about the TOUCH® Prescribing Program or speak to one of our Biogen Case Managers at 1-800-456-2255.

Next: Pivotal Trial

INDICATION

TYSABRI® (natalizumab) is indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. TYSABRI increases the risk of PML. When initiating and continuing treatment with TYSABRI, physicians should consider whether the expected benefit of TYSABRI is sufficient to offset this risk.

IMPORTANT SAFETY INFORMATION

WARNING: Progressive Multifocal Leukoencephalopathy (PML)

TYSABRI® (natalizumab) increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability. Risk factors for the development of PML include the presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants. These factors should be considered in the context of expected benefit when initiating and continuing treatment with TYSABRI.

Healthcare professionals should monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML. TYSABRI dosing should be withheld immediately at the first sign or symptom suggestive of PML. For diagnosis, an evaluation including a gadolinium-enhanced MRI scan of the brain and, when indicated, cerebrospinal fluid analysis for JC viral DNA are recommended.

Because of the risk of PML, TYSABRI is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the TOUCH® Prescribing Program.

  • Infection by the JC Virus (JCV) is required for the development of PML
  • There are no known interventions that can reliably prevent PML or that can adequately treat PML if it occurs
  • Postmarketing data suggest that the risk of developing PML may be associated with relative levels of serum anti-JCV antibody compared to a calibrator as measured by ELISA (often described as an anti-JCV antibody index value)
  • MRI findings may be apparent before clinical signs or symptoms suggestive of PML. Monitoring with MRI for signs that may be consistent with PML may be useful, and any suspicious findings should lead to further investigation to allow for an early diagnosis of PML, if present. Consider monitoring patients at high risk for PML more frequently. Lower PML-related mortality and morbidity have been reported following TYSABRI discontinuation in patients with PML who were initially asymptomatic compared to patients with PML who had characteristic clinical signs and symptoms at diagnosis
  • PML has been reported after discontinuation of TYSABRI in patients who did not have findings suggestive of PML at the time of discontinuation. Patients should continue to be monitored for any new signs or symptoms that may be suggestive of PML for at least 6 months after discontinuation of TYSABRI
  • Adverse events that may occur during plasma exchange (PLEX) include clearance of other medications and volume shifts, which have the potential to lead to hypotension or pulmonary edema. Although PLEX has not been prospectively studied in TYSABRI-treated patients with PML, it has been used in such patients in the postmarketing setting to remove TYSABRI more quickly from the circulation. There is no evidence that PLEX has any benefit in the treatment of opportunistic infections such as PML
  • JCV infection of granule cell neurons in the cerebellum, i.e., JCV granule cell neuronopathy (GCN), with symptoms similar to PML, has been reported in patients treated with TYSABRI. JCV GCN can occur with or without concomitant PML and can cause cerebellar dysfunction. Diagnosis and management of JCV GCN should follow guidance provided for PML
  • Immune reconstitution inflammatory syndrome (IRIS) has been reported in the majority of TYSABRI-treated patients who developed PML and subsequently discontinued TYSABRI. In almost all cases, IRIS occurred after PLEX was used to eliminate circulating TYSABRI. It presents as a clinical decline in the patient’s condition after TYSABRI removal (and, in some cases, after apparent clinical improvement) that may be rapid, can lead to serious neurological complications or death, and is often associated with characteristic changes in the MRI. TYSABRI has not been associated with IRIS in patients discontinuing treatment with TYSABRI for reasons unrelated to PML. In TYSABRI-treated patients with PML, IRIS has been reported within days to several weeks after PLEX. Monitoring for development of IRIS and appropriate treatment of the associated inflammation should be undertaken

Contraindications

  • TYSABRI is contraindicated in patients who have or have had PML
  • TYSABRI is contraindicated in patients who have had a hypersensitivity reaction to TYSABRI

TYSABRI TOUCH Prescribing Program

  • Because of the risk of PML, TYSABRI is available only through a restricted distribution program under a REMS called the TOUCH® Prescribing Program
  • Patients must be enrolled in the TOUCH Prescribing Program, read the Medication Guide, understand the risks associated with TYSABRI, and complete and sign the Patient Enrollment Form

Herpes Infections – Encephalitis, Meningitis and Acute Retinal Necrosis

  • TYSABRI increases the risk of developing encephalitis and meningitis caused by herpes simplex and varicella zoster viruses
  • Serious, life-threatening, and sometimes fatal cases have been reported in the postmarketing setting in multiple sclerosis patients receiving TYSABRI
  • The duration of treatment with TYSABRI prior to onset ranged from a few months to several years
  • Monitor patients receiving TYSABRI for signs and symptoms of meningitis and encephalitis. If herpes encephalitis or meningitis occurs, TYSABRI should be discontinued, and appropriate treatment for herpes encephalitis/meningitis should be administered
  • Patients being administered TYSABRI are at a higher risk of acute retinal necrosis (ARN), a fulminant viral infection of the retina caused by the family of herpes viruses. Patients with eye symptoms such as decreased visual acuity, redness or eye pain should be referred for retinal screening as serious cases of ARN can lead to blindness of one or both eyes
  • Following clinical diagnosis of ARN, consider discontinuation of TYSABRI

Hepatotoxicity

  • Clinically significant liver injury, including acute liver failure requiring transplant, has been reported in patients treated with TYSABRI in the postmarketing setting
  • Signs of liver injury, including markedly elevated serum hepatic enzymes and elevated total bilirubin, occurred as early as six days after the first dose; signs of liver injury have also been reported for the first time after multiple doses
  • TYSABRI should be discontinued in patients with jaundice or other evidence of significant liver injury (e.g., laboratory evidence)

Hypersensitivity/Antibody Formation

  • Hypersensitivity reactions have occurred in patients receiving TYSABRI, including serious systemic reactions (e.g., anaphylaxis) which occurred at an incidence of <1%
  • Reactions usually occur within 2 hours of the start of the infusion. Symptoms associated with these reactions can include urticaria, dizziness, fever, rash, rigors, pruritus, nausea, flushing, hypotension, dyspnea, and chest pain
  • If a hypersensitivity reaction occurs, discontinue administration of TYSABRI and initiate appropriate therapy. Patients who experience a hypersensitivity reaction should not be re-treated with TYSABRI
  • Hypersensitivity reactions were more frequent in patients with antibodies to TYSABRI compared with patients who did not develop antibodies to TYSABRI in both MS and CD studies
  • Patients who receive TYSABRI for a short exposure (1 to 2 infusions) followed by an extended period without treatment are at higher risk of developing anti-natalizumab antibodies and/or hypersensitivity reactions on re-exposure, compared to patients who received regularly scheduled treatment

Immunosuppression/Infections

  • The immune system effects of TYSABRI may increase the risk for infections
  • In Study MS1, certain types of infections—including pneumonias and urinary tract infections (including serious cases), gastroenteritis, vaginal infections, tooth infections, tonsillitis, and herpes infections—occurred more often in TYSABRI-treated patients than in placebo-treated patients. One opportunistic infection, a cryptosporidial gastroenteritis with a prolonged course, was observed in a patient who received TYSABRI in Study MS1
  • In Studies MS1 and MS2, an increase in infections was seen in patients concurrently receiving short courses of corticosteroids. However, the increase in infections in TYSABRI-treated patients who received steroids was similar to the increase in placebo-treated patients who received steroids
  • In a long-term safety study of patients, opportunistic infections (pulmonary mycobacterium avium intracellulare, aspergilloma, cryptococcal fungemia and meningitis, and Candida pneumonia) have been observed in <1% of TYSABRI-treated patients
  • Concurrent use of antineoplastic, immunosuppressant, or immunomodulating agents may further increase the risk of infections over the risk observed with use of TYSABRI alone
  • In Studies MS1 and MS2, the rate of any type of infection was approximately 1.5 per patient-year in both TYSABRI-treated patients and placebo-treated patients
  • In Study MS1, the incidence of serious infections was approximately 3% in TYSABRI-treated patients and in placebo-treated patients. Most patients did not interrupt treatment with TYSABRI during infections

Laboratory Test Abnormalities

  • In clinical trials, TYSABRI was observed to induce increases in circulating lymphocytes, monocytes, eosinophils, basophils, and nucleated red blood cells. Observed changes persisted during TYSABRI exposure, but were reversible, returning to baseline levels usually within 16 weeks after the last dose. Elevations of neutrophils were not observed. TYSABRI induces mild decreases in hemoglobin levels (mean decrease of 0.6 g/dL) that are frequently transient

Thrombocytopenia

  • Cases of thrombocytopenia, including immune thrombocytopenic purpura (ITP), have been reported with the use of TYSABRI in the postmarketing setting. Symptoms of thrombocytopenia may include easy bruising, abnormal bleeding, and petechiae. Delay in the diagnosis and treatment of thrombocytopenia may lead to serious and life-threatening sequelae. If thrombocytopenia is suspected, TYSABRI should be discontinued
  • Cases of neonatal thrombocytopenia, at times associated with anemia, have been reported in newborns with in utero exposure to TYSABRI. A CBC should be obtained in neonates with in utero exposure to TYSABRI

Adverse Reactions

  • The most common adverse reactions reported at an incidence of ≥10% with TYSABRI and ≥2% difference with placebo were headache (38% vs 33%), fatigue (27% vs 21%), infusion reactions (24% vs 18%), urinary tract infections (21% vs 17%), arthralgia (19% vs 14%), depression (19% vs 16%), pain in extremity (16% vs 14%), rash (12% vs 9%), gastroenteritis (11% vs 9%), and vaginitis (10% vs 6%)
  • The most frequently reported serious adverse reactions in Study MS1 were infections (3.2% vs 2.6% placebo), including urinary tract infection (0.8% vs 0.3%) and pneumonia (0.6% vs 0%), acute hypersensitivity reactions (1.1% vs 0.3%, including anaphylaxis/anaphylactoid reaction [0.8% vs 0%]), depression (1.0% vs 1.0%, including suicidal ideation or attempt [0.6% vs 0.3%]), and cholelithiasis (1.0% vs 0.3%)
  • Based on animal data, TYSABRI may cause fetal harm. TYSABRI should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus

Please see full Prescribing Information, including Boxed Warning.

JCV=John Cunningham virus; RMS=relapsing multiple sclerosis.

Start TYSABRI
Start TYSABRI Risk of Relapsing MS Dosing & Administration Coverage & Reimbursement QuickStart Infusion Center Locator Biogen Support Services
Pivotal Trial,
Safety, and
Efficacy
Pivotal Trial,
Safety, and
Efficacy Pivotal Trial Side Effects PML Risk
Additional Studies
Additional Studies Onset CDI QoL TOP 10 TOP 15 Global Safety Study NEDA Study
Proposed MOA
Proposed MOA Proposed MOA
TOUCH® Prescribing Program
TOUCH® Prescribing Program TOUCH On-Line iAssist®
Sign Up
FAQs

©2024 Biogen. All rights reserved.
TYS-US-1887 v15 07/24

©2024 Biogen. All rights reserved.
TYS-US-1888 v15 07/24

All trademarks are the property of their respective owners. This site is intended for US Healthcare Professionals only.